SOUTH SAN FRANCISCO, Calif., January 7, 2005 -- Theravance, Inc. (NASDAQ: THRX) announced today that Rick E Winningham, Theravance's chief executive officer, is scheduled to present at the 23rd Annual JP Morgan Healthcare Conference on Monday, January 10, 2005 at 1:30 p.m. PT (4:30 p.m. ET).
Theravance Announces Initiation of Phase 1 Clinical Study with Investigational Medicine for Gastrointestinal Motility Dysfunction South San Francisco, CA, January 3, 2005 - Theravance, Inc. (NASDAQ: THRX) announced today that it has enrolled the first subjects in a Phase 1 clinical study designed
Theravance To Report Third Quarter 2004 Financial Results November 3, 2004 SOUTH SAN FRANCISCO, CA / October 19, 2004 - Theravance, Inc. (Nasdaq: THRX) announced today that it will release financial results for the period ended September 30, 2004 after market close on Wednesday, November 3, 2004
SOUTH SAN FRANCISCO, CA / May 11, 2004 -- Theravance, Inc., a privately-held pharmaceutical company, announced today that the strategic alliance with GlaxoSmithKline (GSK), previously announced on March 31st, was consummated and funded after receiving the requisite regulatory and Theravance
LONDON, UK and SOUTH SAN FRANCISCO, CA / March 31, 2004 -- GlaxoSmithKline plc (GSK) and Theravance, Inc., a privately-held pharmaceutical company, announced today that they have entered into an innovative broad-based strategic alliance to develop and commercialize novel medicines across a variety
Theravance Announces Positive Phase 2 Results for Once-Daily Beta2-Agonists in Development for Asthma and COPD SOUTH SAN FRANCISCO, CA December 3, 2003/ PR Newswire/ -- Theravance, Inc. announced today that the lead compounds in its alliance with GlaxoSmithKline (GSK) to identify new long-acting,